This white paper provides an in-depth look at the development and challenges of antibody-drug conjugates (ADCs) and how the Synaffix GlycoConnect™ platform, in collaboration with Lonza's Ibex® Design ADC program, addresses these challenges.
ADCs are therapies that combine the specificity of monoclonal antibodies with potent small molecules to target and destroy diseased cells. However, their development is complex and costly due to their structure and cytotoxicity. The Synaffix GlycoConnect™ platform offers stable, site-specific conjugation methods that improve ADC design and manufacturability, addressing issues like premature payload release which can cause off-target toxicities.
The document highlights the integration of Synaffix technology into Lonza's development pipelines, providing a streamlined, end-to-end solution from discovery to clinical production. This integration helps drug developers optimize ADC lead candidates more efficiently while mitigating risks associated with supply chain disruptions and process transfers.
The white paper also discusses the challenges ADC developers face, such as ensuring the quality and efficacy of the components, and how the innovative Synaffix technology platform, combined with Lonza’s Ibex® Design ADC program, can help overcome these challenges and accelerate the path to clinic.